The Mission

Welcome to Antiviral InteliStrat!
Viral diseases represent a real challenge for modern medicine with the recent emergence of new viral threats worldwide such as Ebola, Zika, Avian Influenza, Coronaviruses SARS and MERS, HIV/AIDS, and now SARS-CoV-2 / COVID-19. Reliable information on products and strategies proposed to face this last frontier of infectious diseases remains crucial to support the effective development of new preventive and therapeutic treatments.
Antiviral InteliStrat intends to become the main leading source of information on antiviral drugs and vaccines research and development, and provide its vast knowledge of the virology domain to individuals involved in science, marketing and decision making in the biotech and pharmaceutical industry, as well as the academic community.
To achieve this goal, the company has created and is now offering the following products to its customers:

The Products

1. Database: VIROPENDIUM
2. Documents
3. Other Expertise, Know-how and Support

1. Database

Antiviral InteliStrat has created the most complete, up-to-date Database currently available on antiviral drugs and vaccines. Focused exclusively on viruses, this Database called VIROPENDIUM regroups over 4900 Product files containing detailed information on compounds and vaccines related to prevention or treatment of viral diseases worldwide. VIROPENDIUM is being constantly updated to reflect new developments in the antiviral arena, with thousands of references from PubMed along with insights from News and Press releases of active organizations.

The company is offering this unique source of information on a subscription basis to the biotech and pharmaceutical industry, along with the academia. Customers can access the Database through flexible subscription options designed to fit their specific needs.

Antiviral Database VIROPENDIUM

  • Dedicated only to antiviral drugs and vaccines, with the most complete set of information currently available to scientists, analysts, and drug development / health specialists;
  • Over 4900 Product files on a single web site;
  • More than 1000 sponsors, co-sponsors and organizations included;
  • Over 40 potential modes of action covered for drugs;
  • More than 9 different types of vaccines listed;
  • Includes thousands of references from the scientific literature with links to PubMed
  • Represents products developed worldwide against all viral families causing human diseases;
  • Includes antiviral drugs and vaccines approved for use on the market or at any stage of development, including several products at preclinical and early research stage;
  • Includes antiviral drugs and vaccines that were dropped from clinical trials or were abandoned at various stages of development;
  • Displays hundreds of chemical structures with formulas and molecular weight;
  • Reports mechanism of action and data on viral resistance in the case of drugs;
  • Shows preclinical data and clinical results in human for several products, along with additional information rarely seen on other sites;
  • Includes patent information for many products

A free sample of Database information and Product files is shown in the Database section





Full Access subscription: now only $125*  for a one-year period.

Viral Family Access subscription: now only $50 per year (for any viral family)

Custom Access subscription: you pay only for individual product files ($50 per file)

*all prices in US dollars


Subscriptions made through a secure PayPal® online system

Check out details and complete price list HERE



2. Documents

Based on information collected in its database, Antiviral InteliStrat prepares analyses, reviews and digests covering various aspects of the rapidly evolving antiviral research and development world.

These documents are prepared on a regular basis and made available to help scientists and decision-makers active at different levels in virology, who have time-constraints and need easy-to-read overviews of the antiviral treatment and prevention R&D and market for different types of viruses. The documents aim to cover the following areas:

•    Competitive intelligence
•    Pharma’s current pipeline
•    Specific products and mechanisms of action
•    Research directions and trends
•    Potential collaborations and partnerships (a list of about 380 companies active in antivirals is available)
•    Creative thinking, new ideas and strategies in the lab and at the management level (including a new list of over 350 lead compounds showing positive antiviral activity in lab tests, with chemical structures, activity data and more, classified according to virus types and families)

The documents are listed on the "Documents" page of this website and can be easily dowloaded upon payment through a user-friendly PayPal® online system.


Documents available now:

1. Companies active in Antivirals 2024
2. Viral Vaccines Based on Viral Expression Vectors 2024
3. Respiratory Syncytial Virus R&D status 2024
4. Zika virus R&D status 2024
5. Chikungunya virus R&D status 2024
6. Dengue virus R&D status 2024
7. Coronaviruses R&D status 2024 (including the new SARS-CoV-2 virus)
8. Ebola and Filoviruses R&D status 2024
9. Norovirus R&D status 2024
10. Published Lead Compounds with Antiviral Activity

Check out details HERE



3. Other Expertise, Know-how and Support


Contact us at for details or go to "SERVICES" (bottom of page)